Middle East, North Africa, Afghanistan & Pakistan vs United Kingdom: Access to anti-retroviral drugs, female

Middle East, North Africa, Afghanistan & Pakistan
39.7%
in 2024
United Kingdom
96.0%
in 2023
Middle East, North Africa, Afghanistan & Pakistan rank
17th
United Kingdom rank
14th

Access to anti-retroviral drugs, female over time

  • Middle East, North Africa, Afghanistan & Pakistan
  • United Kingdom
020406080100200020122024

How they compare

United Kingdom currently reports 96.0% against 39.7% in Middle East, North Africa, Afghanistan & Pakistan, a difference of 56.3%.

That makes United Kingdom's figure about 2.4 times Middle East, North Africa, Afghanistan & Pakistan's.

Across all 8 years both countries report, United Kingdom has been ahead every year.

Middle East, North Africa, Afghanistan & Pakistan ranks 17th and United Kingdom ranks 14th of 19 groups.

United Kingdom has averaged higher in every one of the 2 decades both report.

Head to head by decade

Decade Middle East, North Africa, Afghanistan & Pakistan United Kingdom Difference Ahead
2010s 28.6% 88.0% 59.4% United Kingdom
2020s 34.7% 90.8% 56.1% United Kingdom

Averages of every year both report within each decade.

Frequently asked questions

Which has higher access to anti-retroviral drugs, female, Middle East, North Africa, Afghanistan & Pakistan or United Kingdom?
United Kingdom, at 96.0% against 39.7% in Middle East, North Africa, Afghanistan & Pakistan as of 2023.
What is the difference in access to anti-retroviral drugs, female between Middle East, North Africa, Afghanistan & Pakistan and United Kingdom?
56.3%, with United Kingdom ahead.
How many years of comparable data are there for Middle East, North Africa, Afghanistan & Pakistan and United Kingdom?
8 years are reported by both, from 2016 to 2023.
How do Middle East, North Africa, Afghanistan & Pakistan and United Kingdom rank globally for access to anti-retroviral drugs, female?
Middle East, North Africa, Afghanistan & Pakistan ranks 17th and United Kingdom ranks 14th of 19 groups.
Where does this data come from?
UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Middle East, North Africa, Afghanistan & Pakistan vs United Kingdom: Access to anti-retroviral drugs, female. Statizoid, drawing on UNAIDS estimates. Retrieved 19 September 2026, from https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-female-percent/middle-east-north-africa-afghanistan-and-pakistan/united-kingdom/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-female-percent/middle-east-north-africa-afghanistan-and-pakistan/united-kingdom/">Middle East, North Africa, Afghanistan & Pakistan vs United Kingdom: Access to anti-retroviral drugs, female</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.